Business
LIGAND PHARMACEUTICALS INC: TR-Beta Thyroid hormone receptor beta Vernalis Ligand UK Limited (f/k/a Vernalis plc) Verona Verona Pharma plc Viking Viking Therapeutics Xi'an Xintong Xi'an Xintong Pharmaceuticals Research Co.
Revenue increased 60.4% to $268.1M, while Net income increased 3186.6% to $124.5M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $268.1MOK
- Profitability — Net income $124.5MOK
- Cash generation — Free cash flow $48.9MOK
- Insiders — 0 buys; 20 sells in 365 daysNote
- Capital — share repurchases were $15.0MNote
Where the revenue comes from
Fiscal 2025, as LIGAND PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Royalties$161.0M
- Contract Revenue$66.9M
- Contract revenue and income$66.9M
- Captisol$40.2M
Leadership changes
From LIGAND PHARMACEUTICALS INC's own filings, the day they're filed.
- Matthew Korenberg · departureeff. 2024-08-02
- Martine Zimmermann · President · appointmenteff. 2023-09-22
Latest filings
- 8-K · Company announcement2026-09-24
- 8-K · Company announcement2026-09-22
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about LIGAND PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.